(Q43857245)

27 November 2017

title

Chemoprevention with antiestrogens: the beginning of the end for breast cancer. Daniel G. Miller Lecture (English)

1 reference

27 November 2017

1

Jordan VC

1 reference

27 November 2017

language of work or name

English

0 references

publication date

1 December 2001

1 reference

Annals of the New York Academy of Sciences

27 November 2017

published in

1 reference

27 November 2017

volume

952

1 reference

27 November 2017

page(s)

60-72

1 reference

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

27 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2001.TB02728.X

Tamoxifen: a personal retrospective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2001.TB02728.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2001.TB02728.X

A new derivative of triphenylethylene: effect on implantation and mode of action in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2001.TB02728.X

The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2001.TB02728.X

Molecular basis of agonism and antagonism in the oestrogen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2001.TB02728.X

The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2001.TB02728.X

Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2001.TB02728.X

Estrogen, selective estrogen receptor modulation, and coronary heart disease: something or nothing

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2001.TB02728.X

21 January 2018

Antioestrogens. A review

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2001.TB02728.X

Tamoxifen (ICI 46,474) and the human carcinoma 8S oestrogen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2001.TB02728.X

Detection of the 8 S oestrogen-binding component in human uterine endometrium during the menstrual cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2001.TB02728.X

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2001.TB02728.X

Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2001.TB02728.X

A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2001.TB02728.X

Evidence for the metabolic activation of non-steroidal antioestrogens: a study of structure-activity relationships

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2001.TB02728.X

The pharmacology and clinical uses of tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2001.TB02728.X

A realistic clinical perspective of tamoxifen and endometrial carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2001.TB02728.X

Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2001.TB02728.X

Phase II Evaluation of Lyl56758 in Metastatic Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2001.TB02728.X

Metabolites of tamoxifen in animals and man: Identification, pharmacology, and significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2001.TB02728.X

Chemoprevention of mammary carcinogenesis in the rat: combined use of raloxifene and 9-cis-retinoic acid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2001.TB02728.X

Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2001.TB02728.X

Raloxifene as a multifunctional medicine? Current trials will show whether it is effective in both osteoporosis and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2001.TB02728.X

Aspartate 351 of estrogen receptor alpha is not crucial for the antagonist activity of antiestrogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2001.TB02728.X

An antiestrogen-responsive estrogen receptor-alpha mutant (D351Y) shows weak AF-2 activity in the presence of tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2001.TB02728.X

Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2001.TB02728.X

Sequence and expression of human estrogen receptor complementary DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2001.TB02728.X

Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2001.TB02728.X

The oestrogen-like effect of 4-hydroxytamoxifen on induction of transforming growth factor alpha mRNA in MDA-MB-231 breast cancer cells stably expressing the oestrogen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2001.TB02728.X

Selective oestrogen receptor modulation: molecular pharmacology for the millennium

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2001.TB02728.X

Molecular mechanism of action at estrogen receptor alpha of a new clinically relevant antiestrogen (GW7604) related to tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2001.TB02728.X

Peptide antagonists of the human estrogen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2001.TB02728.X

10.1111/J.1749-6632.2001.TB02728.X

21 January 2018

Identifiers

DOI

1 reference

27 November 2017

1 reference